These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 31761273)
41. Variability in prescription medication coverage for children and youth across Canada: A scoping review. Ahmad A; Abbas M; Miregwa B; Holbrook AM Health Policy; 2022 Mar; 126(3):269-279. PubMed ID: 35140016 [TBL] [Abstract][Full Text] [Related]
42. Here today, gone tomorrow: the issue attention cycle and national print media coverage of prescription drug financing in Canada. Daw JR; Morgan SG; Thomson PA; Law MR Health Policy; 2013 Apr; 110(1):67-75. PubMed ID: 23419420 [TBL] [Abstract][Full Text] [Related]
43. Moving toward universal coverage of health insurance in Vietnam: barriers, facilitating factors, and lessons from Korea. Do N; Oh J; Lee JS J Korean Med Sci; 2014 Jul; 29(7):919-25. PubMed ID: 25045223 [TBL] [Abstract][Full Text] [Related]
44. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence. Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812 [TBL] [Abstract][Full Text] [Related]
45. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. Kesselheim AS; Avorn J; Sarpatwari A JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619 [TBL] [Abstract][Full Text] [Related]
46. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase. Trish E; Xu J; Joyce G Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634 [TBL] [Abstract][Full Text] [Related]
47. Australia's 'fourth hurdle' drug review comparing costs and benefits holds lessons for the United States. Lopert R; Elshaug AG Health Aff (Millwood); 2013 Apr; 32(4):778-87. PubMed ID: 23569059 [TBL] [Abstract][Full Text] [Related]
48. Social health insurance contributes to universal coverage in South Africa, but generates inequities: survey among members of a government employee insurance scheme. Goudge J; Alaba OA; Govender V; Harris B; Nxumalo N; Chersich MF Int J Equity Health; 2018 Jan; 17(1):1. PubMed ID: 29301537 [TBL] [Abstract][Full Text] [Related]
49. Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand. Rawson NSB Front Public Health; 2020; 8():544835. PubMed ID: 33194946 [No Abstract] [Full Text] [Related]
50. A comprehensive assessment of universal health coverage in 111 countries: a retrospective observational study. Wagstaff A; Neelsen S Lancet Glob Health; 2020 Jan; 8(1):e39-e49. PubMed ID: 31837954 [TBL] [Abstract][Full Text] [Related]
51. A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. Morgan SG; Gagnon MA; Mintzes B; Lexchin J Healthc Policy; 2016 Aug; 12(1):18-36. PubMed ID: 27585023 [TBL] [Abstract][Full Text] [Related]
52. The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions. Guilcher S; Munce S; Conklin J; Packer T; Verrier M; Marras C; Bereket T; Versnel J; Riopelle R; Jaglal S Health Policy; 2017 Apr; 121(4):389-396. PubMed ID: 28215356 [TBL] [Abstract][Full Text] [Related]
53. Financial risk protection of Thailand's universal health coverage: results from series of national household surveys between 1996 and 2015. Tangcharoensathien V; Tisayaticom K; Suphanchaimat R; Vongmongkol V; Viriyathorn S; Limwattananon S Int J Equity Health; 2020 Sep; 19(1):163. PubMed ID: 32958064 [TBL] [Abstract][Full Text] [Related]
54. Coverage with evidence development for pharmaceuticals: a policy in evolution? Lexchin J Int J Health Serv; 2011; 41(2):337-54. PubMed ID: 21563627 [TBL] [Abstract][Full Text] [Related]
55. Income-related disparities in private prescription drug coverage in Canada. Bolatova T; Law MR CMAJ Open; 2019; 7(4):E618-E623. PubMed ID: 31604712 [TBL] [Abstract][Full Text] [Related]
56. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada. Hanley GE; Morgan S; Barer M; Reid RJ Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859 [TBL] [Abstract][Full Text] [Related]
57. Effects of the Affordable Care Act's young adult insurance expansion on prescription drug insurance coverage, utilization, and expenditures. Look KA; Arora P Res Social Adm Pharm; 2016; 12(5):682-98. PubMed ID: 26632980 [TBL] [Abstract][Full Text] [Related]
58. Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease. Hennessy D; Sanmartin C; Ronksley P; Weaver R; Campbell D; Manns B; Tonelli M; Hemmelgarn B Health Rep; 2016 Jun; 27(6):3-8. PubMed ID: 27305075 [TBL] [Abstract][Full Text] [Related]
59. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Sarnak DO; Squires D; Kuzmak G; Bishop S Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747 [TBL] [Abstract][Full Text] [Related]
60. Should national pharmacare apply a value-based insurance design? Yeung K; Morgan SG CMAJ; 2019 Jul; 191(29):E811-E815. PubMed ID: 31332049 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]